跳至主要内容
临床试验/NCT01565590
NCT01565590终止3 期

Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage

University of Cincinnati1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
4
试验地点
1
主要终点
Changes between serum and CSF cytokines over 48 hours

研究概览

简要总结

The purpose of this research is to compare patients with aneurysmal subarachnoid hemorrhage on dexmedetomidine compared to propofol to assess if one group has decreased inflammation. The investigators hypothesis is that the group assigned to receive dexmedetomidine will have a more profound decrease in markers of inflammation over time.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aneurysmal subarachnoid hemorrhage
  • World Federation of Neurological Surgeons (WFNS) grade 4-5 (see table below)
  • Surgical intervention with clip or coil
  • Placement of cerebrospinal fluid drain (lumbar or ventricular)
  • Mechanically ventilated at start of infusion

排除标准

  • Hemodynamic instability (SBP < 100, HR <60, or on continuous infusion of catecholamines) at screening
  • Heart failure class III or IV (New York Heart Association)
  • Renal failure (RIFLE classification - see table below)
  • Liver failure (serum protein < 3 g/dL and total bilirubin > 5 mg/dL)
  • Known or suspected brain death
  • Pregnancy
  • Unable to receive dexmedetomidine within 48 hours of injury and 4 hours of surgery
  • Allergy to dexmedetomidine
  • Prisoners

研究组 & 干预措施

Propofol

Active Comparator

干预措施: propofol (Drug)

Dexmedetomidine

Experimental

干预措施: Dexmedetomidine (Drug)

结局指标

主要结局

Changes between serum and CSF cytokines over 48 hours

时间窗: 0, 24 and 48 hours

Measure the baseline level (at enrollment) of inflammatory markers tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), glial fibrially acidic protein (GFAP), and malondialdehyde (MDA) as measured in both serum and cerebrospinal fluid (CSF) in 10 patients with aneurysmal subarachnoid hemorrhage (aSAH).

次要结局

  • Hospital length of stay(2 weeks)
  • Glasgow Outcome Scores Extended (GOSE) at discharge(2 weeks)
  • Sedative and analgesic medication requirements(2 weeks)
  • Incidence of delayed cerebral ischemia (DCI)(2 weeks)
  • Sedation scores (RASS and CAM-ICU)(2 weeks)
  • ICU length of stay(2 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shaun Keegan

Clinical Pharmacy Specialist, Critical Care

University of Cincinnati

研究点 (1)

Loading locations...

相似试验